GlassScriptPhysician profile
David P Dimmock
NPI 1275796419
$2,464.17
in general payments reported to CMS, 2019-2025
5 companies · $60.50 in 2025
The $60.50 reported for 2025 was less than what a typical Clinical Biochemical Genetics provider received nationally (typical 2025 total: $237).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2023: $492 · 2024: $44.73 · 2025: $60.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $492 · Education: $60.50 · Food and Beverage: $44.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $491.78 |
| Education | $60.50 |
| Food and Beverage | $44.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $2,339.50 | 2019-2023 | |
| Ptc Therapeutics, INC. | $60.50 | 2025 | Sephience |
| Alexion Pharmaceuticals, INC. | $23.60 | 2024 | Koselugo |
| Ultragenyx Pharmaceutical INC. | $21.13 | 2024 | Dojolvi |
| Upsher-Smith Laboratories LLC | $19.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dimmock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.